BioNTech SE/$BNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Ticker
$BNTX
Sector
Primary listing
Employees
6,772
Headquarters
Website
BioNTech SE Metrics
BasicAdvanced
$24B
-
-$1.67
1.24
-
Price and volume
Market cap
$24B
Beta
1.24
52-week high
$129.27
52-week low
$81.20
Average daily volume
732K
Financial strength
Current ratio
8.607
Quick ratio
8.366
Long term debt to equity
1.174
Total debt to equity
1.457
Interest coverage (TTM)
-42.71%
Profitability
EBITDA (TTM)
-575.225
Gross margin (TTM)
79.76%
Net profit margin (TTM)
-11.98%
Operating margin (TTM)
-26.12%
Effective tax rate (TTM)
11.18%
Revenue per employee (TTM)
$501,000
Management effectiveness
Return on assets (TTM)
-2.14%
Return on equity (TTM)
-1.84%
Valuation
Price to revenue (TTM)
7.206
Price to book
1.3
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-8.106
Free cash flow yield (TTM)
-12.34%
Free cash flow per share (TTM)
-12.388
Growth
Revenue change (TTM)
6.98%
Earnings per share change (TTM)
-31.82%
3-year revenue growth (CAGR)
-48.60%
3-year earnings per share growth (CAGR)
-68.32%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
BioNTech SE News
AllArticlesVideos
BioNTech, Duality score initial trial win with breast cancer precision drug
Reuters3 hours ago
Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Business Wire1 week ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
Reuters4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $24B as of September 05, 2025.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of September 05, 2025.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.